Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer-Reference-Cited by-同舟云学术

Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer

Published:2019-09-30 Issue:5 Volume:39 Page:1152-1164
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Singh Kanchan,Pruski Melissa A.,Polireddy Kishore,Jones Neal C.,Chen Qingzheng,Yao Jun,Dar Wasim A.,McAllister Florencia,Ju Cynthia,Eltzschig Holger K.,Younes Mamoun^ORCID,Moran Cesar,Karmouty-Quintana Harry,Ying Haoqiang,Bailey Jennifer M.

Funder

U.S. Department of Health & Human Services | National Institutes of Health

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-019-1031-z.pdf

Reference73 articles.

1. Cancer Genome Atlas Research Network. Electronic address aadhe, Cancer Genome Atlas Research N. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185–203 e13.

2. Sheridan C, Downward J. Overview of KRAS-driven genetically engineered mouse models of non-small cell lung cancer. Curr Protoc Pharm. 2015;70:14.35.1–16.

3. Vasan N, Boyer JL, Herbst RS. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res. 2014;20:3921–30.

4. Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696.

5. Zhou JX, Yang H, Deng Q, Gu X, He P, Lin Y, et al. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Ann Oncol. 2013;24:1319–25.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ginsenoside Rh2 attenuates the progression of non‐small cell lung cancer by sponging miR‐28‐5p/STK4 axis and inactivating Wnt/β‐catenin signaling;Cancer Medicine;2023-04-20

2. UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity;Cancers;2022-10-29

3. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer;Clinical Science;2022-02

4. A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy;Phytomedicine;2022-02

5. Evaluation of the significance of human class I homeobox A13 and STK4/MST1 expression in conventional colorectal adenoma and adenocarcinoma and correlation with clinicopathological parameters (immunohistochemical study);Egyptian Journal of Pathology;2022